Get to know our clinical trials
A trial to investigate the efficacy and safety of finerenone versus placebo in participants with chronic kidney disease who are not using renin-angiotensin system inhibitors.
EL OBJETIVO DE ESTE ESTUDIO ES EVALUAR QUÉ TAN BIEN FUNCIONA FINERENONA EN PARTICIPANTES CON ERC QUE NO ESTÁN UTILIZANDO INHIBIDORES DEL SISTEMA RENINA-ANGIOTENSINA (SRA). LOS INHIBIDORES DEL SRA SON MEDICAMENTOS QUE REDUCEN LA PRESIÓN ARTERIAL Y CONSTITUYEN EL TRATAMIENTO ESTÁNDAR PARA PACIENTES CON ERC. SIN EMBARGO, ALGUNOS PACIENTES NO PUEDEN TOMAR ESTOS MEDICAMENTOS DEBIDO A EFECTOS SECUNDARIOS U OTROS PROBLEMAS. ESTE ESTUDIO TAMBIÉN EVALUARÁ SI FINERENONA ES SEGURA PARA LOS PARTICIPANTES Y CÓMO AFECTA AL ORGANISMO
Technical Summary
- A GLOBAL, PHASE 3, MULTICENTER, DOUBLE-BLIND, PROSPECTIVE, RANDOMIZED, PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FINERENONE VERSUS PLACEBO IN PARTICIPANTS WITH CHRONIC KIDNEY DISEASE WHO ARE NOT USING RENIN-ANGIOTENSIN SYSTEM INHIBITORS.
- Code EudraCT: 2025-523075-32-00
- Protocol number: 22817
- Promoter: University Medical Center Groningen
- Molecule/Drug: Finerenona
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.